Drug Trial Radar · NCT04890613
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Sep 8, 2021
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Senhwa Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.
Conditions
- Advanced Solid Tumor
Interventions
CX-5461Drug
150 mg sterile lyophilized powder containing 1% sucrose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of Recommended Phase 2 Dose (RP2D)Time frame: Safety cohort review will be conducted every 4 weeks from the date of first patient's enrollment to review safety data, until all patients have been enrolled and evaluated for toxicity.
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Santa Monica, California
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Ohio State University-James Cancer Hospital and Solove Research Institute
Columbus, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.